These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11771656)

  • 1. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.
    Riggs BL; Melton LJ
    J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].
    MMW Fortschr Med; 2004 Mar; 146(10):46. PubMed ID: 15347088
    [No Abstract]   [Full Text] [Related]  

  • 4. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
    Vignot E; Meunier PJ
    Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drugs in development for the treatment of osteoporosis:Raloxifene].
    Taga M
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():572-80. PubMed ID: 11979956
    [No Abstract]   [Full Text] [Related]  

  • 8. [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
    Cyaki O
    Clin Calcium; 2004 Oct; 14(10):39-46. PubMed ID: 15577130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of vertebral fracture risk with raloxifene.
    Bashore R
    J Fam Pract; 1999 Nov; 48(11):911-2. PubMed ID: 10907630
    [No Abstract]   [Full Text] [Related]  

  • 10. Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?
    Hathirat S; Evans MF
    Can Fam Physician; 2001 Oct; 47():1982-4. PubMed ID: 11723592
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C
    N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
    [No Abstract]   [Full Text] [Related]  

  • 13. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Raloxifene hydrochloride].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
    [No Abstract]   [Full Text] [Related]  

  • 15. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
    MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
    [No Abstract]   [Full Text] [Related]  

  • 16. [SERM and quality of bone].
    Sohen S
    Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
    Thiebaud D
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 20. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
    MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.